NASDAQ:BMRN - BioMarin Pharmaceutical Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $89.58 -2.87 (-3.10 %) (As of 12/19/2018 06:52 AM ET)Previous Close$92.45Today's Range$88.12 - $93.2452-Week Range$75.81 - $106.74Volume1.11 million shsAverage Volume747,016 shsMarket Capitalization$16.46 billionP/E Ratio-133.70Dividend YieldN/ABeta1.62 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioMarin Pharmaceutical, Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome. The company's commercial products also comprise Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. Its clinical and pre-clinical product pipeline includes pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria; vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans; valoctocogene roxaparvovec, an AAV5 vector and factor VIII gene therapy drug development candidate for the treatment of severe hemophilia A; BMN 250, an investigational enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B or mucopolysaccharidosis type IIIB; and BMN 290, a selective chromatin modulation therapy for the treatment of Friedreich's ataxia. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has collaboration agreements with Sarepta Therapeutics and Genzyme Corporation; and a license agreement with Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California. Receive BMRN News and Ratings via Email Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:BMRN Previous Symbol CUSIP09061G10 Webwww.bmrn.com Phone415-506-6700 Debt Debt-to-Equity Ratio0.28 Current Ratio2.87 Quick Ratio2.26 Price-To-Earnings Trailing P/E Ratio-133.70 Forward P/E Ratio-639.86 P/E GrowthN/A Sales & Book Value Annual Sales$1.31 billion Price / Sales12.14 Cash FlowN/A Price / Cash FlowN/A Book Value$15.99 per share Price / Book5.60 Profitability EPS (Most Recent Fiscal Year)($0.67) Net Income$-117,040,000.00 Net Margins-8.35% Return on Equity-2.98% Return on Assets-1.83% Miscellaneous Employees2,581 Outstanding Shares178,060,000Market Cap$16.46 billion OptionableOptionable BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions What is BioMarin Pharmaceutical's stock symbol? BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN." How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) issued its quarterly earnings data on Thursday, October, 25th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.22) by $0.15. The biotechnology company had revenue of $391.71 million for the quarter, compared to analysts' expectations of $369.43 million. BioMarin Pharmaceutical had a negative return on equity of 2.98% and a negative net margin of 8.35%. View BioMarin Pharmaceutical's Earnings History. When is BioMarin Pharmaceutical's next earnings date? BioMarin Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for BioMarin Pharmaceutical. What price target have analysts set for BMRN? 20 brokerages have issued 1-year price objectives for BioMarin Pharmaceutical's shares. Their forecasts range from $92.00 to $145.00. On average, they expect BioMarin Pharmaceutical's stock price to reach $116.2778 in the next year. This suggests a possible upside of 29.8% from the stock's current price. View Analyst Price Targets for BioMarin Pharmaceutical. What is the consensus analysts' recommendation for BioMarin Pharmaceutical? 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 5 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioMarin Pharmaceutical. What are Wall Street analysts saying about BioMarin Pharmaceutical stock? Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock: 1. Cantor Fitzgerald analysts commented, ". Reiterate OW and $126 PT. We think progress updates at R&D day today were supportive of the pipeline’s long-term potential. Key takeaways: New vosoritide data was supportive of Ph3 success and BMRN sounds more confident in Valrox accelerated filing after further regulatory interactions. We continue to think that the company’s pipeline is undervalued at this level and we see highly favorable risk/reward into key pipeline updates in 2019. We think the base business alone (without any pipeline) is worth ~$85-$95/sh and that the company’s powerful rare disease and gene therapy platform is underappreciated." (11/4/2018) 2. According to Zacks Investment Research, "BioMarin’s key orphan disease drugs – Vimizim and Kuvan – continue to do well, backed by strong underlying patient demand trends. BioMarin expects sustained growth in both the drugs. The latest FDA approval of Palynziq was the second product approval for BioMarin in less than two years, the first being Brineura in mid-2017. Its impressive rare disease pipeline is also progressing well. However, BioMarin has suffered a few regulatory setbacks related to its pipeline candidates in the past. Further development setbacks can have a negative impact on the stock. Also, Naglazyme and Vimzin revenues vary on a quarterly basis primarily due to infrequent ordering patterns from some countries, mainly Brazil. The stock has outperformed the industry so far this year. Estimates have gone up slightly ahead of the company’s Q3 earnings. However, BioMarin has a rather negative record of earnings surprises in the recent quarters." (10/5/2018) 3. JPMorgan Chase & Co. analysts commented, "BMRN reported an in-line 2Q after the close. Our focus was on early commentary around the Palynziq rollout, which sounds quite favorable relative to prevailing expectations. With solid commercial progress (targeting ~$2B in sales by 2020 pre potential impact of val rox and vosoritide) and major clinical catalysts on the horizon for 2019/20, we continue to have a high level of conviction in the long-term outlook for BMRN. Reiterate OW." (8/5/2018) Has BioMarin Pharmaceutical been receiving favorable news coverage? News headlines about BMRN stock have been trending neutral recently, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BioMarin Pharmaceutical earned a daily sentiment score of 0.1 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. Who are some of BioMarin Pharmaceutical's key competitors? Some companies that are related to BioMarin Pharmaceutical include Bayer (BAYRY), Shire (SHPG), Allergan (AGN), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), Mylan (MYL) and Ono Pharmaceutical (OPHLF). Who are BioMarin Pharmaceutical's key executives? BioMarin Pharmaceutical's management team includes the folowing people: Mr. Jean-Jacques Bienaimé MBA, Chairman & CEO (Age 65)Mr. Daniel K. Spiegelman, Exec. VP & CFO (Age 59)Dr. Robert A. Baffi, Exec. VP of Technical Operations (Age 63)Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 56)Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 60) Who are BioMarin Pharmaceutical's major shareholders? BioMarin Pharmaceutical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Capital Research Global Investors (10.98%), Vanguard Group Inc (8.43%), Primecap Management Co. CA (7.98%), Jennison Associates LLC (6.09%), Capital World Investors (1.38%) and Capital International Investors (1.18%). Company insiders that own BioMarin Pharmaceutical stock include Alan Lewis, Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Richard A Meier, Robert Baffi and V Bryan Lawlis. View Institutional Ownership Trends for BioMarin Pharmaceutical. Which institutional investors are selling BioMarin Pharmaceutical stock? BMRN stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Jennison Associates LLC, American Century Companies Inc., Manning & Napier Group LLC, USS Investment Management Ltd, FIL Ltd, Mitsubishi UFJ Trust & Banking Corp and Pictet Asset Management Ltd.. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include Alan Lewis, Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Richard A Meier, Robert Baffi and V Bryan Lawlis. View Insider Buying and Selling for BioMarin Pharmaceutical. Which institutional investors are buying BioMarin Pharmaceutical stock? BMRN stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, Capital World Investors, First Trust Advisors LP, Marshall Wace North America L.P., TIAA CREF Investment Management LLC, Hsbc Holdings PLC, Renaissance Technologies LLC and Frontier Capital Management Co. LLC. View Insider Buying and Selling for BioMarin Pharmaceutical. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BioMarin Pharmaceutical's stock price today? One share of BMRN stock can currently be purchased for approximately $89.58. How big of a company is BioMarin Pharmaceutical? BioMarin Pharmaceutical has a market capitalization of $16.46 billion and generates $1.31 billion in revenue each year. The biotechnology company earns $-117,040,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis. BioMarin Pharmaceutical employs 2,581 workers across the globe. What is BioMarin Pharmaceutical's official website? The official website for BioMarin Pharmaceutical is http://www.bmrn.com. How can I contact BioMarin Pharmaceutical? BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected] MarketBeat Community Rating for BioMarin Pharmaceutical (NASDAQ BMRN)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 1,116 (Vote Outperform)Underperform Votes: 566 (Vote Underperform)Total Votes: 1,682MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Vote "Outperform" if you believe BMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMRN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/19/2018 by MarketBeat.com StaffFeatured Article: What is the Rule of 72?